公开(公告)号：US20100130740A1

公开(公告)日：2010-05-27

申请号：US12452874

申请日：2008-07-25

申请人： Guiling Zhang ,  Yidong Zhu ,  Chuanwen Fan ,  Minghui Zhang ,  Jingyi Wang

发明人： Guiling Zhang ,  Yidong Zhu ,  Chuanwen Fan ,  Minghui Zhang ,  Jingyi Wang

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： The invention provides a more handy and environment friendly process for preparing risperidone, which comprises reacting 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride with 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one in a basic aqueous solution or suspension. The concentration of alkaline metal carbonates in the basic aqueous solution or suspension is ranged from 15% to 40%. The reaction is carried out at a temperature range of 101-140° C. and the reaction is completed within 10 minutes to 2 hours.

摘要翻译： 本发明提供了一种更方便和环境友好的制备利培酮的方法，其包括使6-氟-3-（4-哌啶基）-1,2-苯并异恶唑盐酸盐与3-（2-氯乙基）-2-甲基-6- 7,8,9-四氢-4H-吡啶并[1,2-a]嘧啶-4-酮在碱性水溶液或悬浮液中的溶液。 碱性水溶液或悬浮液中碱金属碳酸盐的浓度范围为15％至40％。 反应在101-140℃的温度范围内进行，反应在10分钟至2小时内完成。

公开(公告)号：US08637681B2

公开(公告)日：2014-01-28

申请号：US13702956

申请日：2011-03-31

申请人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Boyan Xu ,  Shousheng Yan ,  Zongru Guo ,  Minghui Zhang ,  Dong Lin ,  Zhantao Zhang ,  Haojie Zhou

发明人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Boyan Xu ,  Shousheng Yan ,  Zongru Guo ,  Minghui Zhang ,  Dong Lin ,  Zhantao Zhang ,  Haojie Zhou

IPC分类号： C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D411/06 ,  A61K31/403 ,  A61K31/497 ,  A61K31/535

CPC分类号： C07D403/06 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

摘要： Provided are pyrrolyl substituted dihydroindol-2-one derivatives represented by formula (I), pharmaceutically acceptable salts or solvates of said derivatives, or solvates of said salts, which are effective tyrosine kinase inhibitors. Also provided are the preparation methods of the above compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in manufacturing drugs useful for the treatment or adjunctive treatment of tumors medicated by tyrosine kinases or proliferation or migration of tumor cells driven by tyrosine kinases in mammals (including human).

摘要翻译： 提供由式（I）表示的吡咯基取代的二氢吲哚-2-酮衍生物，所述衍生物的药学上可接受的盐或溶剂合物，或所述盐的溶剂化物，其是有效的酪氨酸激酶抑制剂。 还提供了上述化合物的制备方法，含有这些化合物的药物组合物，以及这些化合物在制备可用于治疗或辅助治疗由酪氨酸激酶药物或由酪氨酸激酶驱动的肿瘤细胞的增殖或迁移的药物中的用途 在哺乳动物（包括人）。

公开(公告)号：US08916574B2

公开(公告)日：2014-12-23

申请号：US13498547

申请日：2010-09-20

申请人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Zhongru Guo ,  Ying Li ,  Shaobo Yang ,  Shousheng Yan ,  Jianrong Zhu ,  Qingmin Yang ,  Minghui Zhang

发明人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Zhongru Guo ,  Ying Li ,  Shaobo Yang ,  Shousheng Yan ,  Jianrong Zhu ,  Qingmin Yang ,  Minghui Zhang

IPC分类号： A01N43/54 ,  A61K31/517 ,  C07D239/72 ,  C07D401/00

CPC分类号： C07D405/04

摘要： The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.

摘要翻译： 本发明涉及作为酪氨酸激酶抑制剂的4-（取代的苯胺基） - 喹唑啉衍生物。 具体地，公开了式I化合物或其药学上可接受的盐或溶剂合物，其中式I中的每个取代基在说明书中定义。 还公开了式I化合物的制备方法，药物组合物及其药物用途。 式I化合物是有效的酪氨酸激酶抑制剂。

公开(公告)号：US20120208833A1

公开(公告)日：2012-08-16

申请号：US13498547

申请日：2010-09-20

申请人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Zhongru Guo ,  Ying Li ,  Shaobo Yang ,  Shousheng Yan ,  Jianrong Zhu ,  Qingmin Yang ,  Minghui Zhang

发明人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Zhongru Guo ,  Ying Li ,  Shaobo Yang ,  Shousheng Yan ,  Jianrong Zhu ,  Qingmin Yang ,  Minghui Zhang

IPC分类号： A61K31/517 ,  A61P35/04 ,  A61P35/02 ,  C07D405/10 ,  A61P35/00

CPC分类号： C07D405/04

摘要： The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.

摘要翻译： 本发明涉及作为酪氨酸激酶抑制剂的4-（取代的苯胺基） - 喹唑啉衍生物。 具体地，公开了式I化合物或其药学上可接受的盐或溶剂合物，其中式I中的每个取代基在说明书中定义。 还公开了式I化合物的制备方法，药物组合物及其药物用途。 式I化合物是有效的酪氨酸激酶抑制剂。

公开(公告)号：US20130158030A1

公开(公告)日：2013-06-20

申请号：US13702956

申请日：2011-03-31

申请人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Boyan Xu ,  Shousheng Yan ,  Zongru Guo ,  Minghui Zhang ,  Dong Lin ,  Zhantao Zhang ,  Haojie Zhou

发明人： Jingyi Wang ,  Chuanwen Fan ,  Long Zhang ,  Boyan Xu ,  Shousheng Yan ,  Zongru Guo ,  Minghui Zhang ,  Dong Lin ,  Zhantao Zhang ,  Haojie Zhou

IPC分类号： C07D403/06

CPC分类号： C07D403/06 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14

摘要： Provided are pyrrolyl substituted dihydroindol-2-one derivatives represented by formula (I), pharmaceutically acceptable salts or solvates of said derivatives, or solvates of said salts, which are effective tyrosine kinase inhibitors. Also provided are the preparation methods of the above compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in manufacturing drugs useful for the treatment or adjunctive treatment of tumors medicated by tyrosine kinases or proliferation or migration of tumor cells driven by tyrosine kinases in mammals (including human).

摘要翻译： 提供由式（I）表示的吡咯基取代的二氢吲哚-2-酮衍生物，所述衍生物的药学上可接受的盐或溶剂合物，或所述盐的溶剂化物，其是有效的酪氨酸激酶抑制剂。 还提供了上述化合物的制备方法，含有这些化合物的药物组合物，以及这些化合物在制备可用于治疗或辅助治疗由酪氨酸激酶药物或由酪氨酸激酶驱动的肿瘤细胞的增殖或迁移的药物中的用途 在哺乳动物（包括人）。

公开(公告)号：US08920835B2

公开(公告)日：2014-12-30

申请号：US13512402

申请日：2010-11-22

申请人： Yong Gan ,  Chunliu Zhu ,  Qingmin Yang ,  Jingyi Wang ,  Xiaoqing Zheng ,  Li Gan ,  Xinxin Zhang

发明人： Yong Gan ,  Chunliu Zhu ,  Qingmin Yang ,  Jingyi Wang ,  Xiaoqing Zheng ,  Li Gan ,  Xinxin Zhang

IPC分类号： A61K9/24 ,  A61K9/28 ,  A61K31/519 ,  A61P25/18 ,  B05D5/00 ,  A61K9/00 ,  A61K9/20 ,  A61K31/517

CPC分类号： A61K9/0004 ,  A61K9/2086 ,  A61K9/2866 ,  A61K31/517

摘要： A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.

摘要翻译： 披露了一种帕培酮双层渗透泵控释片及其制备方法。 双层渗透泵控制释放片剂包括刚性膜，推层，药物层，隔离层和美容涂层，其中刚性膜含有半透性聚合物，致孔剂和/或增塑剂，并且具有 一个或多个药物释放孔在一端，推层包括膨胀材料，渗透剂，粘合剂，着色剂和润滑剂，药物层含有药物活性成分，亲水性聚合物，渗透剂，着色剂 ，润滑剂和抗静电剂，隔离层位于刚性膜的内表面和推层之间，并含有亲水性聚合物。 帕潘立酮双层渗透泵控释片剂在早期阶段呈现出药物释放速率的增加，药物释放速率在后期保持不变。

公开(公告)号：US20120301547A1

公开(公告)日：2012-11-29

申请号：US13512402

申请日：2010-11-22

申请人： Yong Gan ,  Chunliu Zhu ,  Qingmin Yang ,  Jingyi Wang ,  Xiaoqing Zheng ,  Li Gan ,  Xinxin Zhang

发明人： Yong Gan ,  Chunliu Zhu ,  Qingmin Yang ,  Jingyi Wang ,  Xiaoqing Zheng ,  Li Gan ,  Xinxin Zhang

IPC分类号： A61K9/24 ,  B05D5/00 ,  A61P25/18 ,  A61K9/28 ,  A61K31/519

CPC分类号： A61K9/0004 ,  A61K9/2086 ,  A61K9/2866 ,  A61K31/517

摘要： A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.

摘要翻译： 披露了一种帕培酮双层渗透泵控释片及其制备方法。 双层渗透泵控制释放片剂包括刚性膜，推层，药物层，隔离层和美容涂层，其中刚性膜含有半透性聚合物，致孔剂和/或增塑剂，并且具有 一个或多个药物释放孔在一端，推层包括膨胀材料，渗透剂，粘合剂，着色剂和润滑剂，药物层含有药物活性成分，亲水性聚合物，渗透剂，着色剂 ，润滑剂和抗静电剂，隔离层位于刚性膜的内表面和推层之间，并含有亲水性聚合物。 帕潘立酮双层渗透泵控释片剂在早期阶段呈现出药物释放速率的增加，药物释放速率在后期保持不变。

公开(公告)号：US06733436B2

公开(公告)日：2004-05-11

申请号：US10292892

申请日：2002-11-12

申请人： Jian Wang ,  Jingyi Wang

发明人： Jian Wang ,  Jingyi Wang

IPC分类号： A61N100

CPC分类号： A61N2/02 ,  A61N2/002 ,  A61N2005/066 ,  Y10S601/04

摘要： Disclosed is a detachable combination health-care and treatment instrument has a optimal matching parameter, fits the shape of different parts of body, can be used in several parts of body simultaneously, and possesses a energy field multiplexed by a permanent magnetic field, a pulse magnetic field, a thermal effect and far infrared rays. It relates to a health-care and treatment instrument. The instrument includes a main unit, panel units and soft units. In the case of the panel unit, the magnetic induction intensity is 100˜130 mT, the inductance of the coil and the core is 30˜80 mH, and the impedance of the heater panel is 3˜5&OHgr;. In the case of the soft unit, the magnetic induction intensity is ≧100 mT, the inductance of the coil and the core is 30˜80 mH, and the impedance of the sheet heater is 7˜9&OHgr;. Since the present invention has a plurality of panel units and soft units, several parts of body can be positioned into a multiplex energy field simultaneously so that the communication effect of the venation gets better. Furthermore, since it has the optimal matching parameter and adapts the said multiplex energy field to the body so as to achieve the perfect effect of jingluo conduction and health care.

公开(公告)号：US20170044212A1

公开(公告)日：2017-02-16

申请号：US15236055

申请日：2016-08-12

申请人： Jingyi Wang

发明人： Jingyi Wang ,  Jianling Zuo ,  Xiaoliang Lv ,  Tan Zhang

IPC分类号： C07K7/06 ,  A61K38/08

CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K38/08

摘要： The present invention provides a compound (I) for treating sequelae of ischemic cerebral stroke: H—(NH—CHR1—CO)—(NH—CHR2—CO)—(NH—CHR3—CO)—(NH—CHR4—CO)—(NH—CHR5—CO)—(NH—CHR6—CO)—(NH—CHR7—CO)—OH  (I) or a pharmaceutically acceptable salt thereof, wherein R1-R7 are defined herein. The present invention also provides a pharmaceutical composition comprising said compound and use of the same in the manufacture of a medicament for treating sequelae of ischemic cerebral stroke. The compound and pharmaceutical composition according to the present invention have good pharmacological activities so that they are able to improve significantly the symptom of sequelae of ischemic cerebral stroke.

摘要翻译： 或其药学上可接受的盐，其中R 1 -R 7在本文中定义。 本发明还提供了包含所述化合物的药物组合物及其在制备用于治疗缺血性脑卒中后遗症的药物中的用途。 根据本发明的化合物和药物组合物具有良好的药理活性，使得它们能够显着改善缺血性脑卒中后遗症状。

公开(公告)号：US08605765B2

公开(公告)日：2013-12-10

申请号：US12984406

申请日：2011-01-04

申请人： Chen Ji ,  Jingyi Wang ,  Laura M. Giovane

发明人： Chen Ji ,  Jingyi Wang ,  Laura M. Giovane

IPC分类号： H01S5/00

CPC分类号： H01S5/0425 ,  H01S5/06213 ,  H01S5/06226 ,  H01S5/18313 ,  H01S5/2059

摘要： Semiconductor devices are described that include a vertical cavity surface emitting laser (VCSEL) and a structure formed on or near the surface of the VCSEL that acts as a filter that benefits high-frequency VCSEL modulation performance.

摘要翻译： 描述了包括垂直腔表面发射激光器（VCSEL）和形成在VCSEL的表面上或附近的结构的半导体器件，其用作有利于高频VCSEL调制性能的滤波器。